IPA vs. ADAG, AMLX, COYA, KPTI, IMUX, PDSB, CLRB, DMAC, CYTT, and ALLK
Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Adagene (ADAG), Amylyx Pharmaceuticals (AMLX), Coya Therapeutics (COYA), Karyopharm Therapeutics (KPTI), Immunic (IMUX), PDS Biotechnology (PDSB), Cellectar Biosciences (CLRB), DiaMedica Therapeutics (DMAC), Cyteir Therapeutics (CYTT), and Allakos (ALLK). These companies are all part of the "pharmaceutical preparations" industry.
ImmunoPrecise Antibodies (NASDAQ:IPA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
Adagene received 11 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 78.26% of users gave Adagene an outperform vote.
In the previous week, Adagene had 4 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 5 mentions for Adagene and 1 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 1.88 beat Adagene's score of 1.26 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.
6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmunoPrecise Antibodies has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
ImmunoPrecise Antibodies currently has a consensus target price of $7.00, suggesting a potential upside of 530.97%. Adagene has a consensus target price of $5.00, suggesting a potential upside of 78.57%. Given ImmunoPrecise Antibodies' higher possible upside, equities research analysts clearly believe ImmunoPrecise Antibodies is more favorable than Adagene.
Adagene has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -60.23%. Adagene's return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.
Adagene has higher revenue and earnings than ImmunoPrecise Antibodies.
Summary
Adagene beats ImmunoPrecise Antibodies on 11 of the 15 factors compared between the two stocks.
Get ImmunoPrecise Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunoPrecise Antibodies Competitors List
Related Companies and Tools
